Biotech Stocks: Biogen-Elan plunge leads sell-off in biotech

Biogen and Elan both plunged after the companies voluntarily took their multiple sclerosis treatment off the market because of safety concerns. Biogen plunged by 46 percent to $36.63 while Elan lost more than two-thirds of its value, falling 67 percent to $8.83.

The companies said they withdrew the drug, Tysabri, after one patient died and another became seriously ill when the drug was used in conjunction with another MS treatment, Avonex

But the news sent shares of Serono soaring, up 18 percent to $18.26. Removing Tysabri off the market takes away a key threat for Serono's own MS treatment, Rebif.

Biotech Stocks: Biogen-Elan plunge leads sell-off in biotech shares - Biotechnology - General

BioBOOM Op/Ed: Not a great day for biotech investors. We'll see how long this will take to recover. Lots of fear and speculation happening. Some have gone up but mostly taking alot down with this new news. Only adds further to the negativity that Vioxx started a few weeks ago.

The Cost of Living Longer Posted by Hello

How to Save Medicare? Die Sooner

Though Social Security's fiscal direction has taken center stage in Washington of late, Medicare's future financing problems are likely to be much worse. President Bush has asserted that the Medicare Modernization Act, which he signed in 2003, would solve some of those problems - "the logic is irrefutable," he said two months ago. Yet the Congressional Budget Office expects the law to create just $28 billion in savings during the decade after its passage, while its prescription drug benefit will add more than $400 billion in costs. So, how can Medicare's ballooning costs be contained? One idea is to let people die earlier.

The New York Times: How to Save Medicare? Die Sooner

BioBOOM Op/Ed: Smoke em if ya got em

New Virus May Have Come from Monkeys, Experts Say

The two new viruses are called human T-lymphotropic virus types 3 and 4 or HTLV-3 and HTLV-4. They are closely related to two known viruses called HTLV-1 and HTLV-2, which experts believe were transmitted to people, like HIV, from monkeys and apes.

Yahoo! News - New Virus May Have Come from Monkeys, Experts Say

Millipore Forms New Bioscience Division

Millipore Corporation announced that it has formed a new Bioscience Division that will focus on life science research and general laboratory applications of Millipore products and services. The new division combines Millipore's Life Sciences Division and Laboratory Water Division which essentially served the same customer base. The intent is to provide more organizational clarity, improve sales effectiveness, better serve customers, and focus R&D investments in the laboratory area.

Millipore Forms New Bioscience Division

BioBOOM Op/Ed: Anybody smell spin off some day? Gee this strategy looks familiar to some of us...

New HIV Strain Has Very Deadly Aspects

"The unique feature of this case is the convergence of ... the transmission of a remarkably drug-resistant HIV-1 variant and the extremely rapid clinical course to AIDS," the patient's doctors said in a review of his case.

Yahoo! News - New HIV Strain Has Very Deadly Aspects

Genome-Wide Mouse Study Yields Link To Human Leukemia

COLUMBUS , Ohio – Thanks to a handful of very special mice, scientists have discovered a new tumor suppressor gene and a unique chemical signature implicated in the development of human leukemia, findings that open up a “treasure box” of opportunity and possibility, study authors say.

Genome-Wide Mouse Study Yields Link To Human Leukemia

Medical Companies Joining Offshore Trend to India and China

The exporting of jobs is telling evidence that the relentless shifting of employment to countries like India and China that has occurred in manufacturing, back-office work and computer programming is now spreading to a crown jewel of corporate America: the medical and drug industries. Fueling the outsourcing trend are Indian and Chinese scientists who obtained graduate degrees and work experience in the United States and Europe and are now returning to their native countries.

The New York Times > Business > World Business > Medical Companies Joining Offshore Trend

BioBOOM Op/Ed: Ok we understand the interest in cost savings but what we have to ask: does this mean we are losing I.P. that we as tax payers supported? Any grants or studies funded by NIH, lets just speculate, that are in the heads of these folks? Would be interesting to look into that. At least we think so. And by the way, if our source of income is going to be the education end of the deal maybe we should consider increasing some tuition charges from our international guests.

Bird flu virus may spread among people

The Earth may be on the brink of a worldwide epidemic from a bird flu virus that may mutate to become as deadly and infectious as viruses that killed millions during three influenza pandemics of the 20th century, a federal health official said Monday.

Bird flu virus may spread among people

BioBOOM Op/Ed; As we said .... yikes. Think we'll consider liquidating the parakeets too, just in case.

Got Milk?

In a new study of breast milk and store-bought milk from across the United States , scientists at Texas Tech University found perchlorate in every sample but one. The results suggest that this thyroid-disrupting chemical may be more widespread than previously believed

American Chemical Society News Service

Business: Experts warn of health cost shift

Within a decade, the government will be footing the bill for nearly half of the nation's medical costs, its share propelled higher by the new Medicare drug program, administration economists estimated Wednesday

Business: Experts warn of health cost shift

Pfizer acquires Idun Pharmaceuticals

Pfizer today announced that it has entered into an agreement to acquire Idun Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases.

Pfizer acquires Idun Pharmaceuticals:

anti-HIV antibody called 4E10

The antibody 4E10 was derived from HIV-1 infected patients by Dr. Hermann Katinger in Vienna and is the broadest acting neutralizing antibody against HIV-1 that is currently known. This antibody recognizes a protein called gp41 that is found on the surface of the virus. The gp41 protein is thought to play a key role in mediating entry of HIV-1 into human cells.

Research advances quest for HIV-1 vaccine

Medco Health to Buy Accredo in $2.2B Deal

Combined with its own operations, Medco said the deal would create the nation's largest specialty pharmacy business, generating more than $4 billion in annual net revenue from that business alone. Medco's overall revenue was nearly $35.4 billion last year, while Accredo had revenue of $1.7 billion.


Yahoo! News - Medco Health to Buy Accredo in $2.2B Deal

London - Mayor to spend £1million on bird flu drug

Speaking at City Hall, he revealed he was about to sign a contract with drugs firm Roche to safeguard 100,000 police, firefighters, bus and Tube drivers, council workers and City Hall staff. An action plan, which would swing into place in the event of a crisis.

ThisisLondon

BioBOOM Op/Ed: Think this isn't real? Well get ready, because we see the World Health Organization and UN sending out warnings and now, even the mayor of London UK is budgeting to spend £1m on a bird flu drug. Hey soup Nazi we'll have the asian chicken noodle soup with cilatro spicing. HEY??? YOU CALL ME HEY??? And you don't say please?? NO SOUP FOR YOU!

Illumina signs agreement to acquire CyVera for $17.5 million

Illumina Inc. (Nasdaq: ILMN) announced Tuesday that it has signed a definitive agreement and plan of merger with CyVera Corp. in order to facilitate entry into the in-vitro and molecular diagnostics markets. As part of the deal, CyVera will become a wholly owned subsidiary of Illumina


Yahoo! News - Illumina signs agreement to acquire CyVera, reports 2004 results

In Memorium - GONZO

"Excerpt From Hunter S. Thompson's 'Fear and Loathing in Las Vegas:
A Savage Journey to the Heart of the American Dream' (1972):

We were somewhere around Barstow on the edge of the desert when the drugs began to take hold. I remember saying something like 'I feel a bit lightheaded; maybe you should drive' And suddenly there was a terrible roar all around us and the sky was full of what looked like huge bats, all swooping and screeching and diving around the car, which was going about a hundred miles an hour with the top down to Las Vegas. And a voice was screaming: 'Holy Jesus! What are these goddamn animals?'

Then it was quiet again. My attorney had taken off his shirt and was pouring beer on his chest, to facilitate the tanning process. 'What the hell are you yelling about?' he muttered, staring up at the sun with his eyes closed and covered with wraparound Spanish sunglasses. 'Never mind,' I said. 'It's your turn to drive.' I hit the brakes and aimed the Great Red Shark toward the shoulder of the highway. No point mentioning the bats, I thought. The poor bastard will see them soon enough. "

Rapid HIV test slow to catch on with doctors

A 20-minute HIV test would encourage more people to find out their status and get treatment, reducing their chances of spreading the disease, health officials said. Research has shown that people who realize they are HIV positive reduce risky behaviors by up to 70%. But the test hasn't lived up to its potential, because — so far — most physicians don't offer it. "There's still a lot of fear and misunderstanding around rapid tests among many doctors," says Dr. Howard Grossman, president of the American Academy of HIV Medicine.

Rapid HIV test slow to catch on with doctors

BioBOOM Op/Ed: Just to note a potential conflict of interest in posting this article - We are long OSUR.

Drug-ad limits could spread

A Food and Drug Administration advisory panel's recommendation to ban drugmakers from marketing certain pain medicines directly to consumers could be the first step toward limiting a lucrative privilege the government granted the drug industry eight years ago. The FDA's 1997 decision to make it easier for drug companies to tailor commercials for the public opened up the advertising floodgates--especially on nightly television--and is now blamed, in part, for the skyrocketing of health-care costs the past several years.


Chicago Tribune | Drug-ad limits could spread


BioBOOM Op/Ed: Guess the intelligentsia will decide what we get to know. Thats so gratifying. Ok so television, radio, or print ads will be a problem to communicate through. Wonder about websites or blogs? Hope the industry marketing communication folks get their act together but then again it's only as good as the data...

Picture Phones May Make a Doctor's House Calls

Yahoo! News - Picture Phones May Make a Doctor's House Calls

Experimental Prognostic Test Identifies Breast Cancer Patients at Greatest Risk for Metastasis

This diagnostic tool is being developed by Veridex, LLC, a Johnson & Johnson company. The test identifies which breast cancer patients are at greatest risk for metastatic disease did so with more than 90 percent sensitivity, according to a study published in The Lancet (February 19, 2005; vol. 365: issue 9460). The assay represents the first prognostic molecular marker that could be used with all lymph-node-negative (LNN) breast cancer patients.


Experimental Prognostic Test Identifies Breast Cancer Patients at Greatest Risk for Metastasis

TB Case Infects 400 People in Dutch City

More than 400 people have tested positive for tuberculosis infection in the central Dutch city of Zeist, the city said Friday in a statement. Only one case was potentially contagious.


The New York Times > International > Europe > TB Case Infects 400 People in Dutch City

Crick Papers Added to NLM Profiles in Science Site

The U.S. National Library of Medicine (NLM) is presenting an extensive selection from the papers of Francis Crick on its Profiles in Science Web site. The collection represents a close collaboration between the NLM, a part of the U.S. National Institutes of Health, and the Wellcome Library for the History and Understanding of Medicine in London, which holds the Crick papers.

Scientific Computing

U. Wisconsin scientists eliminate stem cell barrier

Stem-cell research is one step closer to clinical applications in humans due to a new discovery reducing contamination in the potentially beneficial therapy. University of Wisconsin and WiCell Research Institute scientists have created a recipe that allows researchers to efficiently develop stem cells without the use of mouse-derived "feeder" cells, which scientists have long suspected could interfere with clinical treatment in humans.


U-WIRE.com/U. Wisconsin scientists eliminate stem cell barrier

Bush Signs Bill to Curb Class-Action Suits

As President Bush signed legislation Friday aimed at discouraging multimillion-dollar class-action lawsuits, he made clear he had his sights set on much broader restraints. Next up, Bush said, should be curbs on asbestos litigation and medical malpractice awards.

Yahoo! News - Bush Signs Bill to Curb Class-Action Suits

BioBOOM Op/Ed: So was it the FDA hearings or this development that caused both Merk and Pfizer's stock price to jump higher today? Probrably both. Looks like Mr. Edwards career choice, out of legal practice, and into politics was the right move. And no more movies about Erin Brockovich

Gene 'Signature' May Predict Breast Cancer Relapse

Between 60 and 70 percent of women with breast cancer that has not spread to the lymph nodes are cured by local surgery or radiotherapy. But 85-90 percent of them still receive additional chemotherapy because doctors fear their cancer will recur.

John Foekens and colleagues from Erasmus MC Rotterdam, Netherlands, said on Friday they had found patterns of gene expressions across 76 genes which could successfully predict relapse


Health News Article | Reuters.com

Celebrex to stay on the Market

"We need to find the unique patients that will benefit from this drug and work out what they need to be told," said meeting Chairman Alistair J.J. Wood of Vanderbilt University Medical School.


The committees were asked to assess the drugs after Merck & Co. pulled Vioxx from the market last fall because of health concerns. Since then questions have been raised about Bextra and Celebrex, both made by Pfizer Inc.


Yahoo! News - FDA Panel: Celebrex Should Stay on Market

BioBOOM Op/Ed: Looks like a big black box warning label will be the answer.... just like the marlboro man. A cynical view would be that the hearings were designed to mimimize litigation and damages from class action. All comes down, as most things, to Risk - Reward assessment but it would be nice to get some kind of responder measuring tool to screen prior and monitor patients. Some day we hope. If all drugs have risk and all drugs have benefits maybe approval should have a committment that the submitting company will also fund some kind of monitoring tools besides asking a pill popper if they have symptoms and slapping a warning label in fly speck font on the bottles.

Scientists Map Important Gene Variation

In a major step toward one day offering gene-based customized medicine, scientists on Thursday unveiled the first map of common human genetic variations — patterns of DNA differences that may help forecast people's disease risks and best treatments.

Yahoo! News - Scientists Map Important Gene Variation

BioBOOM OP/Ed: Like we were saying, Its a wonderful life! Can I see the MAP please as I would like to know my route.

Inherited gene may increase risk for prostate cancer by 50%

Inherited gene may increase risk for prostate cancer by 50%

Young Blood Gets New Meaning with Fresh Study

Scientists at Stanford University found that wiring up an old mouse to the blood stream of a young one gave a major boost to muscle recovery time in the older one.

Health News Article Reuters.com

BioBOOM OP/Ed: Oh maybe the defrocked priest Paul Shanley had something. In a related story the President's father reconsiders his stance on fetal stem cell research after a vigorous workout. Oh.... we crack ourselves up.

Gen-Probe Signs Agreement With Roche for HPV

"Developing an HPV test is an important part of Gen-Probe's long-term strategy to enter new markets where there are important medical needs and attractive commercial opportunities," said Henry L. Nordhoff, chairman, president and chief executive officer of Gen-Probe. "A highly sensitive and specific HPV assay will fit perfectly with our strong STD franchise, and be an ideal high-volume test to expand the menu of our fully automated, high- throughput TIGRIS(R) system."

Gen-Probe Signs Agreement With Roche to Purchase Products for APTIMA(R) Human Papillomavirus Assay

BioBOOM Op/Ed: Hey Digene, sounds like big storm coming your way.

Forbes.com: The Baby, The Bathwater And The Medicine Chest

Medicines are chemicals that alter the way the body works. "Give me a drug without a side effect," a drug researcher once said, "and I'll show you a drug that doesn't work."

Forbes.com: The Baby, The Bathwater And The Medicine Chest

BioBOOM Op/Ed: Ok, let's SCREAM - all together now: DO A #$^% EXPRESSION ANALYSIS FIRST !!! We think a writer from Forbes might offer some suggestions. Seems like pharma is going to look like deer in the headlights during the ongoing advisory hearings anyways. Yea there is risk but there are also new tools available and more coming to minimize that risk and monitor therapy. Will we soon seen pharma and some of the known drug store distribution systems like CVS work to not only deliver medications but become a location to drop off a monitoring sample? If the era of 1 pill- a billion people are coming to an end there has to be a distribution system for things to flow the other way too. At least that's our prediction. JNJ buys RightAide and Lab Corp? Affy installs new therapy array systems at all Wall Drug stores? Hey it's a flyer! Also, if the hearings beat down Merk's stock much more its time to double up!

Bush Makes Acting FDA Commissioner's Job Permanent

FDA Acting FDA Commissioner Lester M. Crawford has received President Bush's nod to assume the post of Commissioner of Food and Drugs at the Department of Health and Human Services.


"Dr. Crawford has dedicated his career to advancing the nation's public health and will lead the way as we enter a new era of individualized medicine and rapidly developing science," Secretary of Health and Human Services Mike Leavitt.

DNC: Health News - Bush Makes Acting FDA Commissioner's Job Permanent

QIAGEN Adds Novel Technology for Haplotype Specific Extraction (HSE)

The Haplotype Specific Extraction (HSE) method physically separates DNA into its haploid components by exploiting the heterozygous differences between gene variants and enables clinicians and researchers to determine the exact location of a mutation on both haploid copies of the genome. Most diseases, cell functions and differences in patient's drug response rates are related to different mutations on different genes of the genome. The precise determination of mutations on the same chromosome or on different chromosomes can be important in the clinical prognosis of diseases, HLA typing with transplantations, pharmacogenomics or oncology testing. The technology has been validated for use in concert with a suite of QIAGEN's magnetic bead-based and automated DNA purification solutions.

Press Release:
QIAGEN Adds Novel Technology for Haplotype Specific Extraction (HSE)

BioBOOM Op/Ed: Seems with the NIH budget and concern of minimal research $ growth in 2005/06 everyone is running after molecular diagnostic markets. The battle is engaged between Qiagen and Invitrogen (Dynal), especially in the HLA arena and mag bead protocols in 2005, even if Invitrogen lacks automation/platforms to execute a complete system solution strategy. Watch the push to leverage other areas such as labeling and media. One question is: where is Applera in the front end game? Nice for Roche MDx that all will be fighting to give them new innovation. And what ever happpened to the small, private, one trick salt-out pony, Gentra? Oh well, pass the fries we need to salt em. And to think that the old Chapt 11 Oncor could have owned this market, now that's humorous!

Coffee May Help Prevent Liver Cancer

A study of more than 90,000 Japanese found that people who drank coffee daily or nearly every day had half the risk of liver cancer as those who never drank coffee.

Yahoo! News - Coffee May Help Prevent Liver Cancer

BioBOOM Op/Ed: In a related story Starbucks offers free Hepatitis screening at their stores.... just kidding... Pass the Java please

Mayo Clinic identifies key cellular process in prostate and other cancers

"Mayo Clinic researchers are the first to identify an interaction between two cellular proteins -- Skp2 and FOXO1 -- that is important for the growth and survival of cancer cells. Researchers also show that this interaction can be chemically reversed to stop cancer tumor growth -- a strategy that may lead to new and better cancer treatments. "


Scientific paper:

http://www.pnas.org/cgi/reprint/102/5/1649

More on the developement
Mayo Clinic identifies key cellular process in prostate and other cancers:

FDA to Create New Drug Safety Board

The FDA said on Tuesday it was creating a new drug safety board to improve the monitoring of medicines already in the marketplace, a response to charges the agency has failed to protect the public from dangerous side effects.

David Webster, a consultant at Webster Consulting Group, said the creation of the safety board may benefit drug companies as it will shift some of the burden of liability for safety from the pharmaceutical industry to the government. "Plaintiffs and class action lawsuits will have a harder time making the argument that consumers were not aware of product risk," said Webster


Yahoo! News - FDA to Create New Drug Safety Board

BioBOOM Op/Ed: Ok this is an interesting development. Looks more political than practical. The real issue to be addressed is the lack of use of some of the new molecular tools to monitor drugs in the early trial and development phases. Including the understanding that people respond differently and can, as we see, have a decidedly different metabolic uptake or effect once the drug is out in the market place. We have numerous new genetic and proteomic tools, plus improved IT data systems but instead we seem to continue to use an almost archaic system of monitoring and feedback. More and more we need to push for acceptance and use of those tools despite the resistance due to cost or sadly ignorance. Well if pharma doesn't wake up as we can see the attorney's are but then again maybe this proposal negates that. Like we said, interesting development

Scientists Document Complex Genomic Events Leading To The Birth Of New Genes

Identifying and characterizing genes that are responsible for primate or human distinctiveness has been a major challenge to scientists. However, this work by Bork and his colleagues should further enable studies focused on the molecular basis for species specificity. "A thorough functional characterization of the other 21 new genes we've identified in this study would reveal the functionally most relevant areas for primate evolution," Bork says

Scientists Document Complex Genomic Events Leading To The Birth Of New Genes

BioBOOM Op/ED: Hey Monkey Boy! It's all about chromosome 2.... Bryan says, "I do not think about things I don't think about." Darrow asks, "Do you think about the things you do think about?"

Compound Fights Gleevec-Resistant Leukemia

The study, published in the February issue of Cancer Cell, found that a compound called AMN107 effectively blocked proliferation of Bcr-Ab1-dependent cells taken from CML patients. Bcr-Ab1 is a protein that's abnormally active in many CML patients. AMN107 proved to be a more potent inhibitor of Bcr-Ab1 than Gleevec (imatinib), inhibiting the growth of cells expressing numerous Bcr-Ab1 mutations resistant to Gleevec.


Yahoo! News - Compound Fights Gleevec-Resistant Leukemia

Reprogrammed HIV Can Hunt Down Cancer Cells

This disabled form of the virus was able to spread through the body and infect cells, but without causing disease. Researchers stripped off HIV's viral coat and reprogrammed the virus to recognize and attach to P-glycoproteins, molecules located on the surface of many cancer cells. They also loaded the altered HIV with a fluorescent protein, the same protein that makes fireflies glow. Using a special optical camera, they used this fluorescence to track the virus' movements after injection into the mice."The virus traveled through the animal's bloodstream and homed straight to the cancer cells in the lungs, where the melanoma had migrated," Chen said.

Yahoo! News - Reprogrammed HIV Can Hunt Down Cancer Cells

Abbott & OraSure Set HIV Test Distribution Deal

Abbott Laboratories Inc. (ABT) on Monday said it has reached a deal to distribute an HIV test developed by OraSure Technologies Inc. (OSUR).Under the terms of the agreement, Abbott is the exclusive distributor to hospitals of OraSure's OraQuick Advance rapid antibody test for the detection of antibodies to HIV-1 and HIV-2, according to a statement."

Top News Article | Reuters.com:

Gene Therapy Restores Hearing in Deaf Animals

NEW YORK (Reuters Health) - By transferring a gene that regulates fundamental cell development into the inner ear of deafened guinea pigs, researchers have regenerated so-called hair cells and partially restored the animals' hearing


Yahoo! News - Gene Therapy Restores Hearing in Deaf Animals

Clone your pet?

Dan, a 40-something investment counselor from Southern California, became the second paying client to receive a pet clone when Genetic Savings & Clone (GSC) officials delivered a kitten to his door on Tuesday, February 8. "Little Gizmo" is a clone of Gizmo, his mixed breed Siamese who died at age 13 in March 2004.

Correction -- Genetic Savings & Clone, Inc.

BioBOOM Op/Ed: We have decided to clone our neighbor's all night barking dog so we can return the favor in a few years.

Drug Regulators Are Trying to Quash Study, Senator Says

The panel has been convened to discuss whether Celebrex and Bextra, heavily selling arthritis pills from Pfizer, hurt the heart and are worth their potential risks. But top officials of the Food and Drug Administration have forbidden Dr. David Graham, a drug-safety officer at the agency, to discuss before the panel a large study of that very question, said Dr. Gurkirpal Singh of Stanford University School of Medicine, Dr. Graham's co-author. "We have significant new information that will alter the thinking about these drugs," Dr. Singh said. "I don't understand why they won't let us present this information."


The New York Times > Washington > Drug Regulators Are Trying to Quash Study, Senator Says

The BIOS Initiative - open source biotechnology is born

BioBOOM Op/Ed: In a publication today in the journal Nature, a team at CAMBIA in Canberra unveils what they call an open source biotechnology toolkit. They claim the concept will allow the public-sector, small to medium enterprises and even large firms worldwide to explore new business models and begin a new era of transparent and cost-effective innovation in life sciences. Should be interesting to watch and see if this takes hold and what the costs are for this sermon on the mount plan for biotechnology..." hey pass the bread basket, Peter!"

The BIOS Initiative - open source biotechnology is born:

Chiron Part 2: SEC investigation now formal

As per earlier posting, Chiron came under scrutiny in October after U.K. regulators impounded almost all of Chiron's flu vaccine supply, after contamination problems were discovered at the company's primary manufacturing facility in Liverpool, England.

Chiron: SEC investigation now formal - Biotechnology - Company Announcements - Earnings

BioBOOM Op/Ed: Seems like it comes full circle as in, like the saying goes; "follow the money". Chiron rose to prominence with the discovery of HCV and moved into drug and vaccine development as the HCV cash cow kept being milked. We remember back in the very early days ($2 a share) of what's a chiron and their non-peer reviewed announcement to the market that solved the non-A non-B hepatitis situation in blood banking. We only hope it's not a loose lips sinks ships situation.

FDA: Chiron making progress at plant - Feb. 11, 2005

WASHINGTON (Reuters) - Chiron Corp. is making progress in fixing the problems at its British vaccine plant that cost the United States half its expected flu shot supply this year, a Food and Drug Administration official said Thursday.


FDA: Chiron making progress at plant - Feb. 11, 2005

New Clue Predicts Breast Cancer Behavior

The wound-healing genetic activity seemed to be a better predictor of patient survival than other prognostic markers clinicians commonly use, such as tumor size, node status and patient age. About 30 percent of women with early breast cancer will experience disease spread (metastases), in which case adding chemotherapy to surgery and radiotherapy improves their prognosis, Jacobson explained. However, 70 percent of patients whose cancer doesn't progress don't need chemotherapy. By analyzing wound-response signature in cancerous cells, the researchers correctly identified 90 percent of patients who developed metastases.


Yahoo! News - New Clue Predicts Breast Cancer Behavior

Cytyc Acquires Proxima Therapeutics, Inc.;

Press Releases

Tufts-NEMC researchers identify enzyme that activates cancer cell growth and invasion

Researchers from Tufts-New England Medical Center have identified a long-sought-after enzyme that interacts with a specific protease-activated receptor, PAR1, on breast cancer cells.

"We believe that blocking the MMP-1/PAR1 pathway with the pepducins described in our study could provide a novel therapeutic approach for treating invasive cancers and possibly other tissue remodeling processes such as inflammation and atherosclerosis," said Kuliopulos.

Tufts-NEMC researchers identify enzyme that activates cancer cell growth and invasion

QIAGEN & Roche Molecular Systems Expand Relationship to Provide AmpliLute Media Sample Preparation Kits

Roche Molecular Systems will market media sample preparation kits supplied by Qiagen under its AmpliLute trademark, Qiagen said today.

QIAGEN Announces Supply Agreement With Roche Molecular Systems to Provide AmpliLute Media Sample Preparation Kits

The Worst Has Happened. Time to Sell? [Fool.com: Commentary] February 10, 2005

--many biotech investors like to pepper a portfolio of well-diversified companies with a few chances to swing for the fences. Even those who eschew the riskiest of biotechs still feel the pain of product failure --

The Worst Has Happened. Time to Sell? [Fool.com: Commentary] February 10, 2005


BioBOOM Op/Ed: One of the better opinions on investing in the market. We just love those Motley fool boys and their analysis!

Medicare Cost now projected at $724 billion over a decade

Rising cost projections for the new Medicare drug benefit alarmed U.S. lawmakers on Wednesday and set off renewed calls to restrain spiraling drug prices and allow pharmaceutical imports from Canada.

Yahoo! News - Medicare Cost Estimates Spark Disputes in Congress

BioBOOM Op/Ed: Sure hope we invest more in education because our kids are going to have to be quite productive to pay all the back taxes needed to support these programs and growing deficit. Hey buddy can you spare a pill? Ohhhhh CANADA......

Mass spectrometry, a powerful tool for proteomics

Proteomics Power to the people!
John Yates reports in the 31 Jan 2005 issue of The New Scientist that mass spectrometry is a signature tool in proteomics, but one that is still limited to the experts. Unlike microarrays or RNA interference experiments, MS data doesn't need to be targeted to specific genes or sequences. It's possible to identify protein components from complex mixtures using a process called shotgun proteomics. The researcher doesn't need to purify proteins or know of a particular protein's existence, but can use the mass data as a key to look up protein addresses in sequence databases for identification. Recent advancements in the technology, such as increases in speed and sensitivity make this technique ammenable to large scale protein analyses in cells or subcellular compartments.

So, how can this technique become more mainstream? According to Yates, cutting-edge biology will advance as scientists from different disciplines collaborate. In his own words:

"The development of innovative and robust technologies for proteomics must democratize large-scale analyses rather than preserve them for the elite. MS technology should be placed into the hands of biologists. There is just too much new biology to be discovered for this not to happen." -- John Yates



Dolly Scientist Gets Human Cloning License

The scientist who attracted the world's attention by cloning Dolly the Sheep is about to take another major step for medical research: cloning human embryos and extracting stem cells to unravel the mysteries of muscle-wasting illnesses like Lou Gehrig's disease. The experiments do not involve creating cloned babies, but the license has nonetheless stirred fresh controversy over the issue and prompted abortion foes and other biological conservatives to condemn the decision.


Yahoo! News - Dolly Scientist Gets Human Cloning License

Invitrogen To Acquire Dynal

CARLSBAD, Calif. and OSLO, Norway--(BUSINESS WIRE)--Feb. 8, 2005--Invitrogen Corporation (NASDAQ: IVGN) today announced it has signed a definitive agreement to acquire privately held molecular separation and purification technology pioneer Dynal Biotech from majority owner Nordic Capital and a co-investor for approximately NOK 2.5 billion. Dynal is the industry leader in magnetic bead technologies that are used in cell separation and purification, cell stimulation, protein research, nucleic acid research and microbiology. The acquisition will provide Invitrogen with bead-based isolation technologies that can be leveraged across the company's broad technology portfolio. In addition, Dynal is a major supplier of specialized magnetic particles to major diagnostic product manufacturers for use in high-throughput automated immunoassay and other instrument systems."

BioBOOM OpEd: As they jump head first into sample prep with the 2nd purchase, they cover alot of ground in the area and an entry into diagnostics with Dynal's HLA business.

Bad Teeth/Gums Equal Bad Heart

Yahoo! News - Study Adds Evidence -- Researchers believe the bacteria that cause the gum disease may spread into the bloodstream and stimulate the immune system, causing inflammation that results in the clogging of arteries. Hardening of the arteries involves the inflammation process, and other studies have strongly linked heart disease with inflammation.


Yahoo! News - Study Adds Evidence -- Bad Teeth Equal Bad Heart


BioBOOM OpEd: Brush Brush Bush and reminds us of a joke: What's worse than having your doctor tell you that you have VD? Having your dentist tell you..... Ok, ok, it's a slow day.

International HapMap Project, Providing over One Billion Genotypes in 2005

Worldwide Public-Private Support Enables Perlegen Sciences to Expand Its Contribution to International HapMap Project, Providing over One Billion Genotypes in 2005

BioBOOM Op/Ed: Welcome to the "Hitchhikers Guide to the Gene Galaxy" The mapping, the detail, the data...THE FUNCTION. Figuring out which genes encode which proteins and how the various proteins relate is the next "big thing". That effort is, well lets say the genome project was like the moon landing, a huge effort and success BUT this is like visiting all the planets. Approximately 30,000 genes in the human genome can encode anywhere from one to as many as a dozen proteins, some of which can be linked to diseases. Therefore the impact on drug development will be significant, almost revolutionary.

Cambodia Confirms Bird Flu in Poultry Near Capital

Yahoo! News - Cambodia Confirms Bird Flu in Poultry Near Capital

BioBOOM OpEd: K.F.C. in CAMBODIA = K.illing F.lu C.hicken. Watch this development closely. 1st Vietnam and now Cambodia. Sure hope we don't see more of this potential pandemic. We'll keep an eye on the situation.



BioBOOM OpEd: White House proposes to increase funding of criminal DNA testing Posted by Hello

NIH approves free access to publicly funded studies

Chicago Tribune NIH approves free access to publicly funded studies:

By Peter Gorner
Tribune science reporter
Published February 4, 2005


After years of heated debates and under pressure from Congress, federal health officials announced Thursday a historic new policy to give the public free access to scientific findings paid for with tax funds."

BioBOOM OpEd: Top story of the day? This could end up to be the TOP story of the Year! If I am a reasearcher there, I would be upset. As a taxpayer, I think - hey it's my money so I should know. As a Biotech busnessman, it opens up alot of opportunities.

China allows first stem cell injection into clinical test

China's Ministry of Science and Technology and Ministry of Health announced in Beijing Tuesday that the country's first stem cell injection was allowed into phase I clinical test for leukemia patients.

This Article was found for you by News Index Customized News Ticker. http://www.newsindex.com/ <>BioBOOM OpEd: This is the new RACE
....not to the moon or more nukes...It's life and health and we are gonna be way behind if things don't change.... Guess that's one way to not worry about social security reform...hey why don't we give out some smokes that would solve the problem...keep the ole life span short. How many frozen 8 cell blastomere's or embryo's have been thrown out in fertility clinics this year?

President Bush says NIH budget funding doubled by Congress in State of Union Speech

"Because a society is measured by how it treats the weak and vulnerable, we must strive to build a culture of life. Medical research can help us reach that goal, by developing treatments and cures that save lives and help people overcome disabilities -- and I thank Congress for doubling the funding of the National Institutes of Health" GWB 2/2/05

BioBOOM OpEd: Was that groundhog day? We don't know where this doubling $ is or better yet is going. Is this really accurate? Double? Anybody have any info? If so, the supply and instrument companies will have a heck of year...a doubled NIH Budget?

New Lymphona Treatment Shows Promise

(NBC News) - A new approach to treating an incurable form of non-Hodgkin's lymphoma is showing promise. Researchers say a one-week course of a drug led to tumor shrinkage in 95 percent of lymphoma patients who hadn't undergone chemo. Seventy-five percent had their tumors completely eliminated. The drug, called Bexxar, works by targeting and delivering radiation to cancer cells. Patients with foliicular lymphoma typically receive months of chemotherapy as their first line treatment and the cancer typically relapses. Researchers say more study is needed to determine the ideal sequence of drugs for these patients. Research was conducted by the University of Michigan. It is published in the New England Journal of Medicine. The Bexxar drug regimen is administered twice in a one week period. The drug is marketed by Glaxosmithkline

A 'gene's kiss' turns on puberty

Scientists say they have found the genetic switch that turns on puberty.
It all starts with a molecule called kisspeptin, which wakes up the reproductive hormones from their childhood hibernation.

The University of Pittsburgh team believe kisspeptin switches on a recently discovered puberty gene, called GPR54.


BBC NEWS Health A 'gene's kiss' turns on puberty

NIH To Bar Staff Scientists From Accepting Drug-company Fees

Washington — Under a far-reaching reform to be announced today, all staff scientists at the National Institutes of Health will be banned from accepting any consulting fees or other income from drug companies, and the employees must also divest industry stock holdings, officials said. The new regulations - drawn up by administrators from NIH, the Office of Government Ethics and the Department of Health and Human Services - will halt lucrative deals that have led to conflict of interest probes at the government's premier agency for medical research, officials said.

Blog Archive